IS1895B - Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum - Google Patents

Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum

Info

Publication number
IS1895B
IS1895B IS3412A IS3412A IS1895B IS 1895 B IS1895 B IS 1895B IS 3412 A IS3412 A IS 3412A IS 3412 A IS3412 A IS 3412A IS 1895 B IS1895 B IS 1895B
Authority
IS
Iceland
Prior art keywords
analogue method
cytidine derivatives
producing cytidine
producing
derivatives
Prior art date
Application number
IS3412A
Other languages
English (en)
Other versions
IS3412A7 (is
Inventor
Fujiu Morio
Ishitsuka Hideo
Miwa Masanori
Umeda Isao
Yokose Kazutera
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS3412A7 publication Critical patent/IS3412A7/is
Publication of IS1895B publication Critical patent/IS1895B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS3412A 1987-11-17 1988-11-16 Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum IS1895B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (2)

Publication Number Publication Date
IS3412A7 IS3412A7 (is) 1989-05-18
IS1895B true IS1895B (is) 2003-10-20

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3412A IS1895B (is) 1987-11-17 1988-11-16 Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum

Country Status (35)

Country Link
US (1) US4966891A (is)
EP (1) EP0316704B1 (is)
JP (1) JPH0678350B2 (is)
KR (1) KR970000241B1 (is)
CN (1) CN1022688C (is)
AR (1) AR247217A1 (is)
AT (1) ATE124951T1 (is)
AU (1) AU619220B2 (is)
CA (1) CA1327358C (is)
CS (1) CS274486B2 (is)
DE (2) DE10199027I2 (is)
DK (1) DK170893B1 (is)
DZ (1) DZ1270A1 (is)
ES (1) ES2074429T3 (is)
FI (1) FI89804C (is)
GR (1) GR3017686T3 (is)
HK (1) HK1003114A1 (is)
HU (1) HU199866B (is)
IE (1) IE883430L (is)
IL (1) IL88363A0 (is)
IS (1) IS1895B (is)
LT (1) LT2185B (is)
LU (1) LU90769I2 (is)
LV (1) LV5624A3 (is)
MC (1) MC1992A1 (is)
MX (1) MX173347B (is)
NL (1) NL300045I2 (is)
NO (2) NO171167C (is)
NZ (1) NZ226923A (is)
PH (1) PH25641A (is)
PT (1) PT89009B (is)
SU (1) SU1736342A3 (is)
UA (1) UA19333A (is)
YU (1) YU47122B (is)
ZA (1) ZA888428B (is)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (is) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) * 1997-05-23 1999-01-25 Pro Bio Sint Srl Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
KR100851272B1 (ko) 2003-12-22 2008-08-08 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
CA2554686A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
RU2392275C2 (ru) * 2004-02-18 2010-06-20 Астразенека Аб Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
WO2006125958A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
WO2007009245A1 (en) 2005-07-21 2007-01-25 Nuvo Research Inc. Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
KR20090090390A (ko) 2006-12-21 2009-08-25 아스트라제네카 아베 Ｇｌｋ 활성제로서 유용한 신규 결정 화합물
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
JP2010524960A (ja) * 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20090122955A (ko) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. 카페시타빈의 제조 방법
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
AU2009278929B2 (en) 2008-08-04 2012-07-05 Astrazeneca Ab Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
KR20120037932A (ko) * 2009-07-23 2012-04-20 시노팜 타이완 리미티드 플루오로시티딘 유도체를 제조하는 방법
RS54972B1 (sr) 2010-03-12 2016-11-30 Genzyme Corp Kombinovana terapija za lečenje raka dojke
HK1206636A1 (zh) 2012-04-02 2016-01-15 Modernatx, Inc. 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
WO2014048939A1 (en) * 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2916840B1 (en) * 2012-11-07 2017-11-01 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine aryl amide analogs
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
HK1220370A1 (zh) 2013-03-15 2017-05-05 Zucai SUO 取代的吉西他滨二环酰胺类似物及使用其治疗的方法
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US10858349B2 (en) * 2016-06-28 2020-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
JP7173613B2 (ja) 2017-04-26 2022-11-16 カールマン，トーマス，アイ． 多標的ヌクレオシド誘導体
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US12110308B2 (en) 2018-01-10 2024-10-08 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AU2019313484A1 (en) * 2018-08-03 2021-02-18 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
JP7625542B2 (ja) 2019-07-17 2025-02-03 ヌクオリオン ファーマシューティカルズ インコーポレイテッド 環状デオキシリボヌクレオチド化合物
EP4143199A4 (en) 2020-04-21 2024-07-03 Ligand Pharmaceuticals, Inc. NUCLEOTIDE PRODRUG COMPOUNDS
CN116710079A (zh) 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
TW202241931A (zh) 2021-01-08 2022-11-01 美商斯特蘭德治療股份有限公司 表現構築體及其用途
KR20250004731A (ko) 2022-04-26 2025-01-08 스트랜드 세러퓨틱스 인코포레이티드 베네수엘라 말 뇌염 (vee) 레플리콘을 포함하는 지질 나노입자 및 이의 용도
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
FI885329A0 (fi) 1988-11-17
PH25641A (en) 1991-08-21
CN1022688C (zh) 1993-11-10
ZA888428B (en) 1989-06-28
SU1736342A3 (ru) 1992-05-23
JPH01153696A (ja) 1989-06-15
LT2185B (lt) 1993-10-15
CS274486B2 (en) 1991-04-11
PT89009B (pt) 1993-02-26
AU619220B2 (en) 1992-01-23
DK640388D0 (da) 1988-11-16
GR3017686T3 (en) 1996-01-31
AR247217A1 (es) 1994-11-30
FI885329L (fi) 1989-05-18
NO171167C (no) 1993-02-03
DK640388A (da) 1989-05-18
YU47122B (sh) 1994-12-28
DZ1270A1 (fr) 2004-09-13
HK1003114A1 (en) 1998-10-09
ES2074429T3 (es) 1995-09-16
NO885106L (no) 1989-05-18
NO2001013I2 (no) 2006-05-01
EP0316704A2 (de) 1989-05-24
JPH0678350B2 (ja) 1994-10-05
DE3854148D1 (de) 1995-08-17
MX173347B (es) 1994-01-03
IL88363A0 (en) 1989-06-30
CN1033183A (zh) 1989-05-31
US4966891A (en) 1990-10-30
NO171167B (no) 1992-10-26
EP0316704B1 (de) 1995-07-12
NL300045I2 (nl) 2002-01-02
AU2516888A (en) 1989-05-25
PT89009A (pt) 1988-12-01
KR890008162A (ko) 1989-07-10
NL300045I1 (nl) 2001-08-01
MX13836A (es) 1993-10-01
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
LU90769I2 (fr) 2001-07-02
KR970000241B1 (ko) 1997-01-08
NZ226923A (en) 1990-10-26
HU199866B (en) 1990-03-28
FI89804B (fi) 1993-08-13
CA1327358C (en) 1994-03-01
YU209188A (en) 1990-08-31
NO885106D0 (no) 1988-11-16
DE10199027I2 (de) 2002-01-31
UA19333A (uk) 1997-12-25
EP0316704A3 (en) 1990-11-22
HUT48267A (en) 1989-05-29
DK170893B1 (da) 1996-03-04
ATE124951T1 (de) 1995-07-15
IS3412A7 (is) 1989-05-18
FI89804C (fi) 1993-11-25
DE10199027I1 (de) 2001-08-02
IE883430L (en) 1989-05-17
CS747588A2 (en) 1990-09-12

Similar Documents

Publication Publication Date Title
IS3412A7 (is) Hliðstæðuaðferð til framleiðslu á cytidine-afleiðum
PT88596A (pt) Process for preparing 2-anilinopyrimidine derivatives useful aspesticidas
BG49923A3 (bg) Метод за получаване на 2-анилино-пиримидинови производни
FI890282L (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI885409A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridatsiiniamiinijohdannaisten valmistamiseksi
FI893100L (fi) Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi
FI894217L (fi) 1-adamantaanijohdannaisten valmistusmenetelmä
PT86660A (pt) Process for preparing adenosine 5:-carboxamide derivatives
FI881904A7 (fi) Menetelmä 3-kefeemijohdannaisten valmistamiseksi
FI895766A7 (fi) Menetelmä uusien lysosfingolipidien valmistamiseksi
FI884627A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten dideoksisytidiinijohdannaisten valmistamiseksi
FI890028A7 (fi) Menetelmä 2-substituoitujen adenosiinijohdannaisten valmistamiseksi
PT87014A (pt) Method for producing ibuprofen
KR860005574A (ko) 뉴클레오시드 유도체의 제조방법
FI890283A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 25-hydroksi-vitamiinin D-johdannaisten valmistamiseksi
FI863776A7 (fi) Menetelmä 7-aminomitosaanijohdannaisten valmistamiseksi.
FI884910A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsopyraanijohdannaisten valmistamiseksi
FI880467A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 3,4-dihydro-2H-bentsopyraanien valmistamiseksi
FI881525A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten N-aryylipiperatsiiniasetamidijohdannaisten valmistamiseksi
FI890257A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
FI893003L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI885560A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
KR880001562A (ko) 알킬페놀류의 제조방법
FI882303A7 (fi) Menetelmä pyrimidiinijohdannaisten valmistamiseksi.
FI891362A7 (fi) Menetelmä uusien alkanofenonien valmistamiseksi